Statement of retraction: Rituximab–cyclophosphamide–dexamethasone combination in management of autoimmune cytopenias associated with chronic lymphocytic leukemia(Leukemia & Lymphoma, (2011), 52, 7(1401-1403), 10.3109/10428194.2011.591005);Rituximab-cyclophosphamide-dexamethasone combination in management of autoimmune cytopenias associated with chronic lymphocytic leukemia

Leukemia and Lymphoma

Volumn 52, Issue 7, 2011, Pages 1401-1403

  Michallet, Anne Sophie ^a   Rossignol, Julien ^b   Cazin, Bruno ^b   Ysebaert, Loic ^c  

^a CENTRE HOSPITALIER LYON SUD   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c CHU PURPAN   (France)

Author keywords

AHAI; CLL; PTI; RCD

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; PREDNISOLONE; RITUXIMAB;

ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNE THROMBOCYTOPENIA; AUTOIMMUNE THROMBOCYTOPENIC PURPURA; AUTOIMMUNITY; CANCER COMBINATION CHEMOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; DISEASE ASSOCIATION; FEMALE; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PURE RED CELL ANEMIA; RELAPSE; SPLENECTOMY; THROMBOCYTOPENIC PURPURA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 79959590563     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428194.2016.1210753     Document Type: Erratum

References (9)

1. Hamblin TJ. Autoimmune complications of chronic lymphocytic leukemia. Semin Oncol 2006;33:230-239.
2. Hallek M, Cheson BD, Catovsky D, et al. International Workshop on Chronic Lymphocytic Leukemia. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008;111:5446-5456.
3. Gupta N, Kavuru S, Patel D, et al. Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia. Leukemia 2002;16: 2092-2095. (Pubitemid 35203453)
4. Kaufman M, Limaye S, Driscoll N, et al. A combination of rituximab, cyclophosphamide and dexamethasone effectively treats immune cytopenias of chronic lymphocytic leukemias. Leuk Lymphoma 2009;50:892-899.
5. Bowen DA, Call TG, Shanafelt T, et al. Treatment of autoimmune cytopenia complicating progressive chronic lymphocytic leukemia/small lymphocytic lymphoma with rituximab, cyclophosphamide, vincristine, and prednisone. Leuk Lymphoma 2010;51:620-627.
6. Zent CS, Ding W, Schwager S, et al. The prognostic significance of cytopenia in chronic lymphocytic leukaemia/small lymphocytic lymphoma. Br J Haematol 2008;141: 615-621. (Pubitemid 351667621)
7. Mauro F, Foa R, Cerretti R, Giannarelli D, Coluzzi S, Girelli G. Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features. Blood 2000;95:2786-2792. (Pubitemid 30235886)
8. Narra K, Borghaei H, Al-Saleem T, Höglund M, Smith, MR. Pure red cell aplasia in B-cell lymphoprliferative disorder treated with rituximab:report of two cases and review of the literature. Leuk Res 2006;30:109-114. (Pubitemid 41654714)
9. D'Arena G, Laurenti L, Capalbo S, et al. Rituximab therapy for chronic lymphocytic leukemia-associated autoimmune hemolytic anemia. Am J Hematol 2006;81:598-602. (Pubitemid 44066170)